Emeritus Professor of Medicine, Perelman School of Medicine
Oncology
Dr. Daniel G. Haller, MD
|
|
Give Review
Daniel Haller is an expert in the field of Oncology. He went to University of Pittsburgh School of Medicine. He has 16 awards "Fellow", "Fellow (FASCO)", "Special Recognition Award", "Statesman Award", "Cino del Duca Award", "Louis Duhring Outstanding Clinical Specialist Award", "Louis A. Cochet Memorial Award in Pancreatic Research", "John H. Glick Teaching Award in Oncology", "Junior Faculty Clinical Fellowship", "Clinical Fellowship", "Alpha Omega Alpha", "Heard Prize in Medicine", "Phi Beta Kappa", "Scholarship", "Trustees Scholarship" and "Super Doctor". Daniel G. Haller, MD is also published. He has 71 publications published. The lastest publication: "Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the...'
Publications
- Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the...
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlle...
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-rela...
- Treatment of colorectal cancer in older patients. International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.
- Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database.
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer.
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
- Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
- Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.
- Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeti...
- What Makes GI Oncology Special?
- Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease.
- Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?
- Thoughts on the Coming Year, ISGIO, and the Future of GI Oncology.
- Provisional clinical opinion.
- Gastrointestinal stromal tumors and neuroendocrine tumors.
- Clinical trials registration: will your study be publishable?
- Bevacizumab beyond progression: does this make sense?
- Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
- Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leu...
- Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
- Accomplishments in gastrointestinal oncology in 2007: conclusion.
- Accomplishments in 2007 in the adjuvant treatment of colorectal cancer.
- Potential regional differences for the tolerability profiles of fluoropyrimidines.
- A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
- New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference.
- Colorectal cancer treatment in the elderly: tailored therapy approaches.
- Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
- Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.
- Metastatic PEComa arising from renal angiomyolipoma: MRI findings.
- Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
- Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
- Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et al.
- Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
- Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
- JCO and the Public Trust.
- Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized t...
- Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
- Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
- Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus.
- Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levami...
- Adjuvant therapy of colon cancer.
- Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers.
- Future directions with angiogenesis inhibitors in colorectal cancer.
- American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
- A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
- Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
- Physician-nurse collaboration in research in the 21st century.
- Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor ...
- Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
- Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence.
- COX-2 inhibitors in oncology.
- Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
- Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
- New perspectives in the management of pancreas cancer.
- Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluoroura...
- Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
- Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection.
- Impact of diabetes mellitus on outcomes in patients with colon cancer.
- Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.
- Chemotherapy for advanced pancreatic cancer.
- Future directions in the treatment of pancreatic cancer.
- Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
- Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
- Chemotherapy for colorectal cancer.
- Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology G...
- A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
- Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
Schools
University of Pittsburgh School of Medicine
Georgetown University Hospital
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellow
- Fellow (FASCO)
- Special Recognition Award
- Statesman Award
- Cino del Duca Award
- Louis Duhring Outstanding Clinical Specialist Award
- Louis A. Cochet Memorial Award in Pancreatic Research
- John H. Glick Teaching Award in Oncology
- Junior Faculty Clinical Fellowship
- Clinical Fellowship
- Alpha Omega Alpha
- Heard Prize in Medicine
- Phi Beta Kappa
- Scholarship
- Trustees Scholarship
- Super Doctor
Education
-
Georgetown University Hospital -
University of Pittsburgh School of Medicine
Hospital
-
Hospital of the University of Pennsylvania
Helpful Reviews
Similar Doctors
|
|
Dr. Adam D. Cohen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan D. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tal Z. Zaks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander E. Perl, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rudolph E. Willis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua M. Bauml, MD
This Doctor is OpenDoctor Recommended.
|